drugset
drugset / Trial / NCT05143307

Long-Term Follow-Up Study of HIV-1 Infected Adults Who Received EBT-101

NCT05143307 ↗

Phase 1 Enrolling by invitation 9 enrolled Excision BioTherapeutics
NaSingle-groupOpen-labelOther

Summary

Participants who receive EBT-101 in a parent protocol will be eligible to participate in this long-term follow-up (LTFU) study (EBT-101-002).

Timeline

Start
2023-07-11
Primary completion
2037-01
Completion
2037-04

Drugs

EvaluationDrugModalityDoseRoute
Background EBT-101 CRISPR / gene editing — —

Indications

HIV infectious disease